• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

工作年龄段人群中存在血脂异常管理差距,他们拥有雇主提供的医疗保险。

Gaps in Dyslipidemia Care Among Working-Aged Individuals With Employer-Sponsored Health Care.

机构信息

Quest Diagnostics Nichols Institute San Juan Capistrano CA.

Stanford Cardiovascular Medicine and Cardiovascular Institute and the FH Foundation Stanford CA.

出版信息

J Am Heart Assoc. 2020 May 5;9(9):e015807. doi: 10.1161/JAHA.119.015807. Epub 2020 Apr 22.

DOI:10.1161/JAHA.119.015807
PMID:32319337
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7428576/
Abstract

Background The American Heart Association and American College of Cardiology guidelines defined patient-management groups that would benefit from lowering of low-density lipoprotein cholesterol (LDL-C). We assessed gaps in dyslipidemia care among employees and spouses with health benefits. Methods and Results We studied 17 889 employees and spouses who were covered by an employer-sponsored health plan and participated in an annual health assessment. Using medical claims, laboratory tests, and risk assessment questionnaires, we found that 43% of participants were in one of 4 patient-management groups: secondary prevention, severe hypercholesterolemia (LDL-C ≥190 mg/dL at least once in the preceding 5 years), diabetes mellitus, or elevated 10-year risk of cardiovascular disease. To assess gaps in dyslipidemia care, we used LDL-C ≤70 mg/dL as the goal for both the secondary prevention group and those in the elevated 10-year risk group with >20% risk; LDL-C ≤100 mg/dL was used for the other groups. Among those in patient-management groups, 27.3% were in the secondary prevention group, 7.4% were in the severe hypercholesterolemia group, 29.9% were in the diabetes mellitus group, and 35.4% were in the elevated 10-year risk group. About 74% of those in patient-management groups had above-goal LDL-C levels, whereas only 31% had evidence of a lipid-lowering therapy in the past 6 months: 45% in the secondary prevention group, 31% in the severe hypercholesterolemia group, 36% in the diabetes mellitus group, and 17% in the elevated 10-year risk group. Conclusions The substantial gaps in LDL-C treatment and goal attainment among members of an employer-sponsored medical plan who were mostly aware of their LDL-C levels indicate the need for gap-closure initiatives.

摘要

背景

美国心脏协会和美国心脏病学会指南定义了将从降低低密度脂蛋白胆固醇(LDL-C)中获益的患者管理人群。我们评估了有健康福利的员工及其配偶的血脂异常治疗差距。

方法和结果

我们研究了 17889 名参加雇主赞助的健康计划并参加年度健康评估的员工及其配偶。使用医疗记录、实验室检查和风险评估问卷,我们发现 43%的参与者属于以下 4 种患者管理组之一:二级预防、严重高胆固醇血症(过去 5 年内至少有一次 LDL-C≥190mg/dL)、糖尿病或心血管疾病 10 年风险升高。为了评估血脂异常治疗的差距,我们将 LDL-C≤70mg/dL 作为二级预防组和 10 年风险升高(≥20%)组的目标;对于其他组,使用 LDL-C≤100mg/dL。在患者管理组中,27.3%处于二级预防组,7.4%处于严重高胆固醇血症组,29.9%处于糖尿病组,35.4%处于 10 年风险升高组。约 74%的患者管理组 LDL-C 水平高于目标值,而在过去 6 个月内仅有 31%有降脂治疗证据:二级预防组为 45%,严重高胆固醇血症组为 31%,糖尿病组为 36%,10 年风险升高组为 17%。

结论

在雇主赞助的医疗计划中,大多数患者知晓自己的 LDL-C 水平,但 LDL-C 治疗和目标达标方面存在很大差距,这表明需要采取差距关闭措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/89eba1cb1566/JAH3-9-e015807-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/88147acb0204/JAH3-9-e015807-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/8f5471d390ec/JAH3-9-e015807-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/34475324b24c/JAH3-9-e015807-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/4c2b180c143e/JAH3-9-e015807-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/b1df49cd3aef/JAH3-9-e015807-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/89eba1cb1566/JAH3-9-e015807-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/88147acb0204/JAH3-9-e015807-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/8f5471d390ec/JAH3-9-e015807-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/34475324b24c/JAH3-9-e015807-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/4c2b180c143e/JAH3-9-e015807-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/b1df49cd3aef/JAH3-9-e015807-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/7428576/89eba1cb1566/JAH3-9-e015807-g006.jpg

相似文献

1
Gaps in Dyslipidemia Care Among Working-Aged Individuals With Employer-Sponsored Health Care.工作年龄段人群中存在血脂异常管理差距,他们拥有雇主提供的医疗保险。
J Am Heart Assoc. 2020 May 5;9(9):e015807. doi: 10.1161/JAHA.119.015807. Epub 2020 Apr 22.
2
Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).血脂控制不理想:来自非干预性俄罗斯中央调查血脂异常治疗不足 II 期研究(CEPHEUS II)的结果。
Cardiovasc Diabetol. 2017 Dec 16;16(1):158. doi: 10.1186/s12933-017-0641-4.
3
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.改善他汀类药物治疗策略以降低 LDL 胆固醇:2 型糖尿病患者和非 2 型糖尿病患者达标相关因素。
Cardiovasc Diabetol. 2021 Jul 16;20(1):144. doi: 10.1186/s12933-021-01338-y.
4
Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.降脂治疗与急性冠状动脉综合征后 LDL-C 目标达标:一项丹麦基于人群的队列研究。
BMC Cardiovasc Disord. 2020 Jul 13;20(1):336. doi: 10.1186/s12872-020-01616-9.
5
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.在高和极高心血管风险患者中使用调脂治疗和降低低密度脂蛋白胆固醇目标达标情况:来自德国的真实世界证据。
Atherosclerosis. 2018 Jan;268:99-107. doi: 10.1016/j.atherosclerosis.2017.11.020. Epub 2017 Nov 20.
6
The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components.2013年美国心脏病学会/美国心脏协会胆固醇管理指南:消除无争议部分的困惑
Tex Heart Inst J. 2016 Aug 1;43(4):313-4. doi: 10.14503/THIJ-16-5798. eCollection 2016 Aug.
7
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.低密度脂蛋白胆固醇≥190mg/dL患者降脂治疗使用情况的差异:来自国家心血管数据注册库 - 实践创新与临床卓越注册库的见解
Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004652. doi: 10.1161/CIRCOUTCOMES.118.004652.
8
Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).18 个西欧以外国家的低密度脂蛋白胆固醇目标达标情况:国际胆固醇管理实践研究(ICLPS)。
Eur J Prev Cardiol. 2018 Jul;25(10):1087-1094. doi: 10.1177/2047487318777079. Epub 2018 May 17.
9
[Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].[接受降脂治疗的血脂异常患者动脉粥样硬化性心血管疾病一级和二级预防中胆固醇目标达成情况:中国血脂异常防治研究(DYSIS-China)亚组分析]
Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Aug 24;44(8):665-70. doi: 10.3760/cma.j.issn.0253-3758.2016.08.006.
10
Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.美国心脏病学会/美国心脏协会(ACC/AHA)胆固醇指南对几种美国社区卫生中心网络中糖尿病患者心血管疾病预防中他汀类药物未充分利用的影响。
J Am Heart Assoc. 2017 Jul 3;6(7):e005627. doi: 10.1161/JAHA.117.005627.

引用本文的文献

1
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications.临床医护人员给予降脂药物的考虑因素。
Am J Cardiovasc Drugs. 2024 Nov;24(6):729-741. doi: 10.1007/s40256-024-00665-1. Epub 2024 Aug 13.
2
Social Determinants of Health Challenges Are Prevalent Among Commercially Insured Populations.商业保险人群中普遍存在健康挑战的社会决定因素。
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211025162. doi: 10.1177/21501327211025162.

本文引用的文献

1
Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France.75 岁时停止他汀类药物用于一级预防对心血管的影响:法国一项全国范围内基于人群的队列研究。
Eur Heart J. 2019 Nov 14;40(43):3516-3525. doi: 10.1093/eurheartj/ehz458.
2
Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease.他汀类药物依从性与动脉粥样硬化性心血管疾病患者死亡率的关系。
JAMA Cardiol. 2019 Mar 1;4(3):206-213. doi: 10.1001/jamacardio.2018.4936.
3
Assessing Changes in Statin Prescribing Patterns Surrounding the 2013 American College of Cardiology/American Heart Association Lipid Guidelines.
评估 2013 年美国心脏病学会/美国心脏协会脂质指南发布后他汀类药物处方模式的变化。
Clin Ther. 2019 Feb;41(2):314-321. doi: 10.1016/j.clinthera.2018.12.017. Epub 2019 Jan 25.
4
Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.基于日本行政索赔数据的动脉粥样硬化性心血管疾病患者和糖尿病患者的血脂异常药物治疗依从性和持久性。
Atherosclerosis. 2019 Mar;282:19-28. doi: 10.1016/j.atherosclerosis.2018.12.026. Epub 2018 Dec 29.
5
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018 年美国心脏病学会/美国心脏协会/美国心血管血管造影和介入学会/美国预防、物理治疗和康复医师学会/美国糖尿病协会/美国老年学会/美国药学会/美国医师协会/美国生理学会/北美介入放射学会/美国国家脂质协会/美国临床内分泌医师协会胆固醇管理指南:美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.
6
Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities.高免赔额健康保险计划对心血管药物依从性和健康差异的影响。
Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004632. doi: 10.1161/CIRCOUTCOMES.118.004632.
7
Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy.日本高心血管风险患者开始他汀类药物治疗的治疗模式、他汀类药物不耐受和随后的心血管事件。
Circ J. 2018 Mar 23;82(4):1008-1016. doi: 10.1253/circj.CJ-17-0811. Epub 2017 Dec 23.
8
Optimizing Cholesterol Treatment in Patients With Muscle Complaints.优化有肌肉不适症状患者的胆固醇治疗。
J Am Coll Cardiol. 2017 Sep 5;70(10):1290-1301. doi: 10.1016/j.jacc.2017.07.752.
9
Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.2013ACC/AHA 血胆固醇指南对动脉粥样硬化性心血管疾病患者他汀类药物治疗模式和低密度脂蛋白胆固醇的影响。
J Am Heart Assoc. 2017 Mar 17;6(3):e004909. doi: 10.1161/JAHA.116.004909.
10
Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.2013年美国心脏病学会/美国心脏协会胆固醇指南对因急性冠状动脉综合征或中风住院患者高强度他汀类药物处方的影响。
Am Heart J. 2016 Nov;181:130-136. doi: 10.1016/j.ahj.2016.07.024. Epub 2016 Aug 26.